Pitt Shield

A Review of the Current Therapies, Challenges, and Future Directions of Transcranial Focused Ultrasound Technology: Advances in Diagnosis and Treatment.

Authors: Krishna V, Sammartino F, Rezai A

Magnetic resonance imaging-guided focused ultrasound ablation has been approved for the treatment of refractory essential tremor and is being studied for other neurological indications, including dyskinesias and tremor in Parkinson disease, dystonia, neuropathic pain, obsessive-compulsive disorder, epilepsy, and brain tumors. To review the scientific foundations of FUS technology, existing neurological applications, and future advances. PubMed was searched for the past 10 years using the terms "transcranial ultrasound," "focused ultrasound," and "neurological applications." Relevant references were selected from the author's reference collection. From the 2855 unique records, 243 publications were screened. After excluding abstracts detailing in vitro studies or non-neurological applications, 86 full texts were retrieved for qualitative review. Advances in the transducer design and electronic phase correction have allowed efficient focusing of ultrasounds for transcranial treatment. The mid-frequency (650 kHz) transducer can make small (4-6 mm in diameter) and precise (accuracy of <2 mm) brain lesions. The treatment monitoring is achieved via "live" anatomical thermography imaging and clinical feedback. The initial results from its clinical application in movement disorders are encouraging. Emerging applications in epilepsy and neurobehavioral and cognitive disorders are being explored. The low-frequency (220 kHz) transducer coupled with microbubbles can potentially enable targeted drug delivery for novel applications, such as Alzheimer disease and brain tumors. Finally, neuromodulation with subthreshold sonications may allow the interrogation of brain areas previously not accessible for electrical stimulation. Transcranial focused ultrasound for both ablative and nonablative applications is noninvasive, making it suitable for selected patients who are not candidates for conventional surgical options. Future advancements in imaging and sonication algorithms will improve the safety and efficacy of this technology.

Introduction

Purpose thermal ablation

Outcomes and Safety

Summary of Outcomes Transcranial focused ultrasound (FUS) is a noninvasive technology for both ablative (650 kHz thermal ablation, FDA-approved for essential tremor) and nonablative applications (low-frequency 220 kHz for targeted drug delivery via BBB opening, and subthreshold sonications for neuromodulation). Key advantages include real-time MRI thermography, subthreshold testing, and no incisions. Limitations include skull heating, patient selection (skull density ratio ≥0.4), treatment envelope (~3 cm radius), and potential adverse effects (gait disturbance, paresthesias). Future advances include tractography-based targeting, functional MRI feedback, and expanded indications for epilepsy, OCD, and brain tumors.

Brain Region

Targeted brain region(s) Not specified

Ultrasound Parameters

We are open to feedback. If you see a mistake or have a suggestion, please contact us.

← Back to Search